{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:41:08Z","timestamp":1790959268458,"version":"4.1.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T00:00:00Z","timestamp":1586995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Carriers of the BRCA1 and\/or BRCA2 mutation incur a lifetime risk of up to 85 per cent for breast cancer, and between 20 and 40 per cent for ovarian cancer. Efforts to estimate the lifetime risk of developing colorectal cancer for BRCA mutation carriers have produced conflicting results. Consequently, there are no formal guidelines regarding the need for bowel screening for individuals with BRCA1 and\/or BRCA2 mutations. This systematic review and meta-analysis determined the risk of colorectal cancer associated with BRCA carrier mutations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The primary outcome was incidence of colorectal cancer in BRCA mutation carriers. Secondary outcomes were the incidence in BRCA1 and BRCA2 carriers, Ashkenazi Jews, and age- and sex-matched cohorts.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Eleven studies were included in the review, with an overall population of 14 252 and 4831 colorectal cancers identified. Nine studies were included in the meta-analysis. There was no increase in colorectal cancer among patients carrying a BRCA mutation (odds ratio 1\u00b703, 95 per cent c.i. 0\u00b780 to 1\u00b732; P\u00a0=\u00a00\u00b782). After adjustment for Ashkenazi heritage, and age and sex estimates, there was no increased odds of developing colorectal cancer (with no heterogeneity, I2 = 0 per cent).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>BRCA1 and\/or BRCA2 mutation carriers are not at a higher risk of colorectal cancer.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/bjs.11603","type":"journal-article","created":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T09:37:02Z","timestamp":1587029822000},"page":"951-959","source":"Crossref","is-referenced-by-count":46,"title":["Risk of colorectal cancer associated with <i>BRCA1<\/i> and\/or <i>BRCA2<\/i> mutation carriers: systematic review and meta-analysis"],"prefix":"10.1093","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9320-1586","authenticated-orcid":false,"given":"C M","family":"Cullinane","sequence":"first","affiliation":[{"name":"Department of Breast Surgery, Cork University Hospital , Cork, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8209-4810","authenticated-orcid":false,"given":"B","family":"Creavin","sequence":"additional","affiliation":[{"name":"Department of General Surgery, University Hospital Kerry , Tralee, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E P","family":"O'Connell","sequence":"additional","affiliation":[{"name":"Department of General Surgery, University Hospital Kerry , Tralee, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Kelly","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Cork University Hospital , Cork, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M J","family":"O'Sullivan","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Cork University Hospital , Cork, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M A","family":"Corrigan","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Cork University Hospital , Cork, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H P","family":"Redmond","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Cork University Hospital , Cork, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,4,16]]},"reference":[{"key":"2022100812515352400_bjs11603-bib-0001","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrc1431","article-title":"BRCA1 and BRCA2: 1994 and beyond","volume":"9","author":"Narod","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"2022100812515352400_bjs11603-bib-0002","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","article-title":"Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies","volume":"72","author":"Antoniou","year":"2003","journal-title":"Am J Hum Genet"},{"key":"2022100812515352400_bjs11603-bib-0003","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S1097-2765(00)80202-6","article-title":"BRCA1 controls homology-directed DNA repair","volume":"4","author":"Moynahan","year":"1999","journal-title":"Mol Cell"},{"key":"2022100812515352400_bjs11603-bib-0004","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1097-2765(01)00174-5","article-title":"BRCA2 is required for homology-directed repair of chromosomal breaks","volume":"7","author":"Moynahan","year":"2001","journal-title":"Mol Cell"},{"key":"2022100812515352400_bjs11603-bib-0005","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10689-010-9378-x","article-title":"BRCA1 mutations and colorectal cancer in Poland","volume":"9","author":"Suchy","year":"2010","journal-title":"Fam Cancer"},{"key":"2022100812515352400_bjs11603-bib-0006","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41431-017-0067-1","article-title":"Phenotypic characteristics of colorectal cancer in BRCA1\/2 mutation carriers","volume":"26","author":"Grinshpun","year":"2018","journal-title":"Eur J Hum Genet"},{"key":"2022100812515352400_bjs11603-bib-0007","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1136\/gut.52.12.1756","article-title":"Prognostic significance of the allelic loss of the BRCA1 gene in colorectal cancer","volume":"52","author":"Garcia","year":"2003","journal-title":"Gut"},{"key":"2022100812515352400_bjs11603-bib-0008","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1245\/ASO.2006.05.021","article-title":"Implication of the BRCA2 and putative \u2018BRCA3\u2019 genes in Dukes' stage C, replication error-negative colon cancer","volume":"13","author":"Sivarajasingham","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"2022100812515352400_bjs11603-bib-0009","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"2022100812515352400_bjs11603-bib-0010","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/cge.12497","article-title":"BRCA1 and BRCA2 mutations and the risk for colorectal cancer","volume":"87","author":"Sopik","year":"2015","journal-title":"Clin Genet"},{"key":"2022100812515352400_bjs11603-bib-0011","author":"Wells","year":"2011","journal-title":"The Newcastle\u2013Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-analyses"},{"key":"2022100812515352400_bjs11603-bib-0012","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1054\/bjoc.2000.1598","article-title":"The frequency of the predominant Jewish mutations in BRCA1 and BRCA2 in unselected Ashkenazi colorectal cancer patients","volume":"84","author":"Chen-Shtoyerman","year":"2001","journal-title":"Br J Cancer"},{"key":"2022100812515352400_bjs11603-bib-0013","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/jnci\/djh006","article-title":"Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer","volume":"96","author":"Kirchhoff","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"2022100812515352400_bjs11603-bib-0014","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/jnci\/djh008","article-title":"BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer","volume":"96","author":"Niell","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"2022100812515352400_bjs11603-bib-0015","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/cncr.29041","article-title":"Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian","volume":"121","author":"Mersch","year":"2015","journal-title":"Cancer"},{"key":"2022100812515352400_bjs11603-bib-0016","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1136\/jmg.2004.028829","article-title":"Netherlands Collaborative Group on Hereditary Breast Cancer (HEBON). Cancer risks in BRCA2 families: estimates for sites other than breast and ovary","volume":"42","author":"van Asperen","year":"2005","journal-title":"J Med Genet"},{"key":"2022100812515352400_bjs11603-bib-0017","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1136\/jmg.2006.048173","article-title":"Cancer risks in carriers of the BRCA1\/2 Ashkenazi founder mutations","volume":"44","author":"Kadouri","year":"2007","journal-title":"J Med Genet"},{"key":"2022100812515352400_bjs11603-bib-0018","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1093\/jnci\/94.18.1358","article-title":"Cancer incidence in BRCA1 mutation carriers","volume":"94","author":"Thompson","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"2022100812515352400_bjs11603-bib-0019","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/bjc.2013.741","article-title":"Hereditary Breast Cancer Study Group. Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study","volume":"110","author":"Phelan","year":"2014","journal-title":"Br J Cancer"},{"key":"2022100812515352400_bjs11603-bib-0020","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1093\/jnci\/djy148","article-title":"BRCA1 and BRCA2 gene mutations and colorectal cancer risk: systematic review and meta-analysis","volume":"110","author":"Oh","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"2022100812515352400_bjs11603-bib-0021","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/cge.12687","article-title":"Is there really an increased risk of early colorectal cancer in women with BRCA1 pathogenic mutations?","volume":"89","author":"Evans","year":"2016","journal-title":"Clin Genet"},{"key":"2022100812515352400_bjs11603-bib-0022","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1056\/NEJM199705153362001","article-title":"The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews","volume":"336","author":"Struewing","year":"1997","journal-title":"N Engl J Med"},{"key":"2022100812515352400_bjs11603-bib-0023","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/jnci\/91.15.1310","article-title":"Cancer risks in BRCA2 mutation carriers","volume":"91","author":"Breast Cancer Linkage Consortium","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"2022100812515352400_bjs11603-bib-0024","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1111\/j.1572-0241.2001.04677.x","article-title":"A systematic review and meta-analysis of familial colorectal cancer risk","volume":"96","author":"Johns","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"2022100812515352400_bjs11603-bib-0025","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1086\/318787","article-title":"Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer","volume":"68","author":"Risch","year":"2001","journal-title":"Am J Hum Genet"},{"key":"2022100812515352400_bjs11603-bib-0026","doi-asserted-by":"crossref","first-page":"e1002742","DOI":"10.1371\/journal.pmed.1002742","article-title":"COSMOS-E: guidance on conducting systematic reviews and meta-analyses of observational studies of etiology","volume":"16","author":"Dekkers","year":"2019","journal-title":"PLoS Med"},{"key":"2022100812515352400_bjs11603-bib-0027","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0140-6736(00)02786-0","article-title":"Does the inclusion of grey literature influence estimates of intervention effectiveness reported in meta-analyses?","volume":"356","author":"McAuley","year":"2000","journal-title":"Lancet"},{"key":"2022100812515352400_bjs11603-bib-0028","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/jebm.12266","article-title":"Grey literature: an important resource in systematic reviews","volume":"10","author":"Paez","year":"2017","journal-title":"J Evid Based Med"},{"key":"2022100812515352400_bjs11603-bib-0029","first-page":"3632","article-title":"Colorectal cancer population screening programs worldwide in 2016: an update","volume":"28","author":"Navarro","year":"2016","journal-title":"World J Gastroenterol"}],"container-title":["British Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbjs.11603","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/bjs\/article-pdf\/107\/8\/951\/46380023\/bjs11603.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjs\/article-pdf\/107\/8\/951\/46380023\/bjs11603.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T13:24:19Z","timestamp":1665235459000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjs\/article\/107\/8\/951\/6094450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,16]]},"references-count":29,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,4,16]]},"published-print":{"date-parts":[[2020,6,15]]}},"URL":"https:\/\/doi.org\/10.1002\/bjs.11603","relation":{},"ISSN":["0007-1323","1365-2168"],"issn-type":[{"value":"0007-1323","type":"print"},{"value":"1365-2168","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,7]]},"published":{"date-parts":[[2020,4,16]]}}}